Drug
Cenicriviroc clinical trials
Also written TBR-652.
- studies test it
- 17
- open now
- 0
- in phase 3
- 1
- first study started
- 2009
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
17 studies that test it; most in 2014 (4)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 4 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 1 |
| 2020 | 2 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 11
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 4
Tobira Therapeutics, Inc. (11) · QuantumLeap Healthcare Collaborative (1) · Novartis Pharmaceuticals (1) · University of Hawaii (1) · Allergan (1) · Charite University, Berlin, Germany (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
Often tested with
Tested in the same studies.
Remdesivir (1) · Imatinib (1) · Dexamethasone (1) · Icatibant (1) · Apremilast (1) · Dornase alfa (1) · Celecoxib (1) · Famotidine (1)
Studies
Open first, then newest update. How each study uses cenicriviroc is read from its arms, and is right about nine times in ten.
Testing it · 17
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill PatientsActive, not recruitingPhase 2QuantumLeap Healthcare CollaborativeNCT04488081Written as Cenicriviroc
- Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIVWithdrawnPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT04334915Written as Cenicriviroc Mesylate (CVC)
- Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver FibrosisCompletedPhase 2Novartis PharmaceuticalsNCT03517540Written as Cenicriviroc (CVC)
- Charité Trial of Cenicriviroc (CVC) Treatment for COVID-19 PatientsTerminatedPhase 2Charite University, Berlin, GermanyNCT04500418Written as Cenicriviroc (CVC)
- AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)TerminatedPhase 3Tobira Therapeutics, Inc.NCT03028740Written as Cenicriviroc
- Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic SteatohepatitisTerminatedPhase 2Tobira Therapeutics, Inc.NCT03059446Written as Cenicriviroc
- Effect of Cenicriviroc on HIV Neurocognitive ImpairmentCompletedPhase 2University of HawaiiNCT02128828Written as cenicriviroc
- ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or Type 2 Diabetes Mellitus (T2DM) and Suspected NAFLDCompletedPhase 2Tobira Therapeutics, Inc.NCT02330549Written as Cenicriviroc 150 mg
- Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver FibrosisCompletedPhase 2Tobira Therapeutics, Inc.NCT02217475Written as Cenicriviroc
- PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Participants With Primary Sclerosing CholangitisCompletedPhase 2Tobira Therapeutics, Inc.NCT02653625Written as Cenicriviroc 150 mg
- Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its MetabolitesCompletedPhase 1AllerganNCT03376841Written as Cenicriviroc
- Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in CombinationCompletedPhase 1Tobira Therapeutics, Inc.NCT02684799Written as Cenicriviroc
- Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in CombinationCompletedPhase 1Tobira Therapeutics, Inc.NCT02342067Written as Cenicriviroc
- Phase 1 Study of Multiple-Dose Pharmacokinetics of Cenicriviroc in Subjects With Mild and Moderate Hepatic ImpairmentCompletedPhase 1Tobira Therapeutics, Inc.NCT02120547Written as Cenicriviroc in mild liver impaired
- Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of MidazolamCompletedPhase 1Tobira Therapeutics, Inc.NCT01827540Written as Cenicriviroc
- A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve PatientsCompletedPhase 1/2Tobira Therapeutics, Inc.NCT01092104Written as TBR-652
- Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic VirusCompletedPhase 2Tobira Therapeutics, Inc.NCT01338883Written as Cenicriviroc 100 mg
As the comparator · 1 — what is tested is compared with cenicriviroc
Codes
What other systems call cenicriviroc · ClinicalTrials.gg INT004860
- MeSH (NLM) C506967cenicrivirocConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 15C116UA4YCENICRIVIROCConfirmed FDA, NLM, Wikidata
- Wikidata Q5058846cenicrivirocConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166464CenicrivirocOne source FDA
- DrugBank DB11758One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C506967 | cenicriviroc | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 15C116UA4Y | CENICRIVIROC | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q5058846 | cenicriviroc | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166464 | Cenicriviroc | One source FDA |
| DrugBank | DB11758 | — | One source Wikidata |
Also registered as cenicriviroc mesylate (UNII R96TV84T21).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.